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Stem cell-like transcriptional reprogramming mediates
metastatic resistance to mTOR inhibition
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V Hernández18, A Martínez-Aranda18, M Martínez-Iniesta16, X Serrat19, J Cerón19, J Brunet20, MP Barretina21, M Gil22, C Falo22,
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A Velasco29, X Matias-Guiu29, A Figueras10, JV Sánchez-Mut30, M Sánchez-Céspedes30, A Cordero30, J Gómez-Miragaya30,
L Palomero1, A Gómez30, TF Gajewski31, EEW Cohen32, M Jesiotr33, L Bodnar34, M Quintela-Fandino35, N López-Bigas36,37,
R Valdés-Mas38, XS Puente38, F Viñals10, O Casanovas10, M Graupera10, J Hernández-Losa39, S Ramón y Cajal39, L García-Alonso5,
J Saez-Rodriguez5, M Esteller30,37,40, A Sierra41, N Martín-Martín42, A Matheu43,44, A Carracedo42,44,45, E González-Suárez30,
M Nanjundan46, J Cortés47, C Lázaro12, MD Odero3, JWM Martens15, G Moreno-Bueno48, MH Barcellos-Hoff4, A Villanueva16,
RR Gomis2,37 and MA Pujana1
Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However,
whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here,
complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis
in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively
regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung
metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures,
and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between
resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.
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INTRODUCTION
The mechanistic target of rapamycin (mTOR) kinase integrates
cues from nutrients and growth factors and is thus a master
regulator of cell growth and metabolism.1 As such, mTOR is
activated in most cancer types and is frequently associated with
poor prognosis.2 Moreover, oncogenic mTOR signaling has a
direct role in promoting cancer progression by inducing a pro-
invasion translational program.3 This program includes the
downregulation of the tuberous sclerosis complex 2 (TSC2) gene,
whose product, in a heterodimer with the TSC1 product, serves as
a negative regulator of mTOR complex 1 (mTORC1).4 Conse-
quently, loss of Tsc2 in mice promotes breast cancer progression
and metastasis.5 Collectively, current knowledge supports the
notion that mTOR signaling has a key role in cancer initiation,
progression and metastasis.
As mTOR is a key factor in cancer biology, therapies based on its
inhibition have been widely studied6 and are central to the
treatment of advanced metastatic breast cancer.7 However, the
success of monotherapy assays has been limited. Critically, within
a relatively short term, allosteric mTOR inhibition concomitantly
induces upstream receptor kinase signaling, which mediates
therapeutic resistance.8 Thus, therapies that combine allosteric
inhibitors (rapamycin (sirolimus) and rapalogs) with inhibitors of
growth factor signaling have been extensively evaluated.9
Intriguingly, recent studies have further linked mTOR activity to
a stem cell-like cancer phenotype that mediates breast cancer
metastasis10,11 and, using triple-negative (TN) breast cancer cell
lines, have described that mTORC1/2 inhibition spares a cell
population with stem cell-like properties and enhanced NOTCH
activity.12 These results are consistent with previous observations
concerning the required activation of mTOR signaling in breast
cancer stem-like viability and maintenance,13 the enhancement of
NOTCH signaling in poorly differentiated breast tumors14 and the
increase of tumor-initiating capacities with mTOR inhibition in
liver cancer.15 In this scenario, a fundamental question emerges as
to whether relative long-term adaptation or resistance to mTOR
inhibition is functionally linked to tumor-initiating properties and,
eventually, metastasis.
Here, we explored the hypothesis that mTOR signaling supports
metastasis and remains active in therapeutic resistance in
metastatic breast cancer. We found that abnormal mTOR signaling
enhances tumor-initiating properties and metastatic potential.
This activity is dependent on EVI1, which in cooperation with
SOX9 sustains a transcriptional reprogramming response.
RESULTS
Active mTORC1 signaling associates with distant metastasis
mTORC1 is the target of one of the latest drugs approved for the
treatment of breast cancer in the advanced metastatic setting,7
which suggests that this protein complex has a potential role in
supporting metastasis and aggressive features. To study this
relationship, a tissue microarray of primary breast tumors was
assessed for mTORC1 activity by means of immunohistochemical
determination of phospho-Ser235/236-ribosomal protein S6 (pS6),
a well-established downstream target of mTORC1.1 An association
between pS6 positivity and the basal-like tumor phenotype or CK5
positivity was observed (Figure 1a; Mann–Whitney test Po0.01).
Most importantly, an association was also detected between
medium-high pS6 positivity and the development of distant
metastases (Fisher’s exact test P= 0.02; odds ratio (OR) = 2.64, 95%
confidence interval (CI) 0.95–7.35). Intriguingly, whereas the
analyses by tumor subtypes were underpowered, both estrogen
receptor (ER)-positive and ER-negative cases suggested a trend
toward increased metastatic risk (ORs = 4.44 and 1.96, respec-
tively). Thus, enhanced mTOR activity and breast cancer meta-
static potential appear to be linked.
Metastasis dependence on mTORC1 signaling
To test the contribution of mTOR signaling to metastasis, we used
the well-defined MDA-MB-231 breast cancer cell line, including its
parental poorly metastatic population and the lung metastatic
derivatives LM1 and LM2.16 Western blot analyses showed
increased levels in LM2 cells of several components of the
mTORC1 signaling pathway, and particularly of RAPTOR and RHEB
across the sub-populations (Figure 1b). The enhanced signaling in
LM2 cells compared with the poorly metastatic parental popula-
tion was confirmed by quantification of immunohistochemical
staining of pS6 in the lung metastases that developed the cells
upon tail vein injection (Figure 1c). Expanding on these
observations, analysis of TCGA data showed negative correlations
between TSC1/2 and an upregulated gene set whose expression
was clinically and experimentally associated with breast cancer
metastasis to lung (lung metastasis signature (LMS)-up; Pearson’s
correlation coefficients (PCCs) o − 0.25; P-values o10− 8). Nota-
bly, this set was derived from the study of LM2 cells.16
Next, we tested the causal role of mTOR activity in the
experimental model of lung metastasis. The capacity of LM2 cells
to colonize the lung was assessed in the presence or absence of
an allosteric mTOR inhibitor. LM2 cells stably expressing green
fluorescent protein (GFP) and luciferase were injected into the
lateral tail vein of immunocompromised mice, which were then
randomly allocated to a group treated with dimethyl sulfoxide
(DMSO) or a group treated with everolimus, both for 38 days.
A significant reduction of lung colonization (and, as expected, of
pS6 intensity) was observed in the latter group, both by
measurements of in vivo photon flux and the relative lung
metastasis area ex vivo by histology (Figure 1d). Collectively, these
data suggest that mTORC1 signaling is associated with breast
cancer metastatic potential and that inhibition of mTOR prevents
lung metastasis. However, it is unclear whether this association
persists in settings of resistance to mTOR inhibitors.
Metastatic resistance to mTOR inhibition
To evaluate the mechanisms responsible for resistance to mTOR
inhibitors, we used two independent metastatic tumor models,
namely a human TN BRCA1-mutated breast tumor orthotopically
engrafted in nude mice (hereafter ortho-xenograft; Supplementary
Figure 1) and the TN 4T1 murine breast carcinoma cell line
engrafted in syngeneic background mice. Cells from both tumor
models showed substantial mTORC1 signaling activity, particularly
at the tumor invasive front (Supplementary Figure 1).17 Unexpect-
edly, although systemic treatment with sirolimus or everolimus
blunted primary tumor growth in each model, it did not reduce
the number or size of lung metastases (Figure 2a). In addition, and
contrary to expectations, the intensity of pS6 staining at the
invasive tumor fronts of the primary lesion and in the lung
metastases of the sirolimus-treated ortho-xenografts was sig-
nificantly higher than in the control animals (Figure 2b). Similarly,
a key factor in cancer metastasis initially identified in LM2 cells
and human data analyses (thus included in LMS-up), FSCN1,16,18
was found to be significantly overexpressed in both experi-
mental models exposed to mTOR inhibitors (Figure 2c).
Subsequent gene expression analysis of the treated tumors
revealed coordinated changes concurrent with mTOR inhibition
that were associated with LMS activation (Supplementary
Figure 2). These changes included overexpression of LMS-up in
the sirolimus-treated ortho-xenografts and underexpression
of LMS-down in the everolimus-treated 4T1 tumors (as measured
by the gene set expression analysis (GSEA), P-valueso0.05;
Supplementary Figure 2).
To further study resistance to allosteric mTOR inhibition, we
subjected MCF7 ER-positive and HCC1937 TN cells to long-term
exposure to 50 and 150 nM of everolimus, respectively. After a
period of sensitivity defined by undetectable or very low levels of
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pS6, both cell lines recovered canonical mTORC1 signaling in
90–120 days (Figure 2d, top panels). Similarly to the in vivo
observations, FSCN1 increased concurrently with adaptation to
everolimus in both cell settings (Figure 2d, bottom panels).
Subsequently, transcriptome analyses showed a significant
change of the LMS in both cell lines, and particularly of the
LMS-up in HCC1937 cells (Supplementary Figure 3).
Interestingly, both everolimus-adapted cell models showed
significantly higher colony-forming capacity, with the higher
relative difference found in HCC1937 cells (Figure 2e). Accordingly,
fluorescence-activated cell sorting revealed an increase of CD49f+
and of CD44+/CD24− cells in everolimus-adapted MCF7 and
HCC1937 cultures, respectively (Figure 2f). Although MCF7 did not
show an increase in CD44+/CD24− , CD49f positivity has been
linked to cancer stem cell-like properties.19 In addition, quantita-
tive gene expression analysis revealed a significant increase of
SOX2 in everolimus-adapted MCF7 cells and, in turn, an increase of
NANOG and OCT4 (but not SOX2) in everolimus-adapted HCC1937
cells (Supplementary Figure 4). Notably, an increase in SOX2, but
not the two additional stem cell-like markers, has also been
described in MCF7 cells resistant to tamoxifen.20 Therefore, by
combining in vivo and in vitro models of breast cancer, we reveal
that exposure to allosteric mTOR inhibitors consistently promotes
metastatic and tumor initiation properties. However, the precise
regulators of this aggressive reprogramming remain to be
determined.
TSC1/2 expression correlates negatively with tumor-initiating
features
Given that differences in colony formation assays and tumor
initiation properties were observed in mTOR inhibitor-resistant cell
populations, we then explored the association between mTOR
signaling and cancer cell initiation features in gene expression
profiles from patient samples. To this end, we computed the
expression correlations between TSC1 or TSC2 (TSC1/2) and 20
previously defined gene expression signatures using breast
cancer data from The Cancer Genome Atlas (TCGA).21 The
signatures (full annotation is provided in Supplementary Table 1)
include a consensus set derived from the study of embryonic stem
cell-like cells (sESCs),22 a consensus set of correlated master
regulators of breast cancer stemness-like functions (hereafter
sMRS),23 and a MYC-centered regulatory network (sMYC);24
importantly, these signatures were originally associated with poor
prognosis and/or metastatic potential of ER-negative breast
cancer and other types of cancer.22–24 The expression profiles of
Figure 1. mTORC1 activity concurrent with enhanced metastatic potential. (a) Left panels, representative immunohistochemical scores
(0, negative, to 3, highest expression) of pS6 staining in the tissue microarray (TMA) of primary breast tumors. Right panel, results for the
association between pS6 staining and distant metastasis. (b) Increased expression of mTORC1 pathway components with enhanced
metastatic potential of MDA-MB-231 cells. The loading control (α-tubulin, TUBA) is shown. Bottom panel, graph showing quantifications of
protein levels relative to parental and TUBA (per sample). (c) Increased pS6 expression in lung metastases developed by LM2 cells. The arrows
mark magnified fields. Right panel, box-and-whisker plots for the quantification (pixels/area, p/a) of pS6 intensity; three mice and three similar
lung metastases were analyzed in each setting. The P-value of the two-tailed Mann–Whitney test is shown. (d) Left panel, graph showing the
in vivo photon flux quantification in mice injected with LM2 and treated with DMSO or everolimus. Representative images from
bioluminescence in lungs from DMSO- or everolimus-treated mice are shown. The scale bar depicts the range of photon flux values as a
pseudo-color display, with red and blue representing high and low values, respectively. Right top panels, quantification of lung colonization
(total metastasis area normalized per total lung area, based on HE). Right bottom panels, representative immunohistochemical results for pS6
and quantification of normalized intensities.
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TSC1/2 were found to be negatively correlated (PCCs o − 0.10; P-
values o0.05) with most of the signatures (Figure 3a). In turn,
positive correlations were observed with the downregulated
genes that characterize mammary epithelial basal and luminal
progenitor cells (Figure 3a).25 Moreover, the expression of TSC1
was positively correlated with a downregulated gene expression
signature associated with oncogenic PI3KCA activity in breast
cancer.26,27 Collectively, these results confirmed that mTOR activity
is associated with stem cell-like gene expression profiles in breast
cancer.
Next, we observed that the sESC, sMRS and sMYC largely
distinguished the expression profiles of mTOR inhibitor-treated
tumors from those treated with DMSO (Figure 3b). The regulators
of the sMRS (originally defined as Core-9)23 were commonly
overexpressed upon mTOR inhibition (Figure 3c). Furthermore, a
strong overexpression of the three signatures was detected when
the ortho-xenografts were allowed to re-grow following treatment
with sirolimus (relative to the DMSO-treated re-growth, GSEA P-
values o0.001; Figure 3d and Supplementary Table 2). Analysis of
the three signatures defined above did not reveal significant
changes in the cell line models, but most of the regulators of sMRS
were found to be overexpressed in HCC1937 cells (Figure 3e).
These results were confirmed by western blot analysis of HMGA1
(Figure 3f), which has been associated with poor prognosis and
metastatic breast cancer.28 The observed differences between the
in vitro and in vivo expression changes may be due to the
molecular specificity and/or biological conditions involved in each
setting. Globally, however, inhibition of mTOR appears to be
coupled to the transcriptional reprogramming that sustains
metastatic and tumor initiation features.
EVI1 couples mTOR signaling to metastasis
Feedback activation of known mediators of resistance to rapalogs
was not observed in the sirolimus-treated ortho-xenografts, but an
increase in phospho-Thr202/Tyr204 ERK (pERK) was detected in
4T1 tumors treated with everolimus (Supplementary Figure 5).
Exome sequence comparison between one DMSO- and one
sirolimus-treated ortho-xenograft did not identify acquired muta-
tions affecting components of the canonical TSC/mTOR pathway
(Supplementary Table 3). In vitro, only modest time-dependent
Figure 2. Metastatic resistance to mTOR inhibition. (a) Left panels, graphs showing the average and standard deviation of micro- and macro-
metastases observed in the lungs of the DMSO- and sirolimus- or everolimus-treated orthoxenografts and 4T1 tumors, respectively. The results
correspond to the last day of treatment, and micro- versus macro-metastases were defined using a 2 mm width threshold, and by examining
at least three tissue levels separated by 4 20 μM. Right panels, growth rates of the DMSO- and sirolimus- or everolimus-treated tumors.
(b) Representative immunohistochemical results for pS6 at the invasive tumor fronts (magnifications; top right panels) and the lung
metastases (right panels) of DMSO- or sirolimus/everolimus-treated mice. The middle panels show quantifications, which correspond to three
tumors, three equal front areas, and three metastases in each case. (c) Representative immunohistochemical tumor results for FSCN1/Fscn1 in
DMSO- or sirolimus/everolimus-treated mice; quantifications are shown in right panels. (d) Recovered pS6 signal with concurrent FSCN1
overexpression through adaptation to everolimus in MCF7 and HCC1937 cells. Days of treatment are shown. (e) Left panel, graph showing the
quantification of colonies from untreated and everolimus-adapted cells (12 culture fields were analyzed). The one-tailed t-test
P-values are shown. Representative images of cell cultures are shown in right panels. (f) Flow cytometry results showing the cell counts
for CD49f/EpCAM and of CD44/CD24 positivity in untreated or everolimus-adapted MCF7 and HCC1937 cells, respectively.
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changes of phospho-S473 AKT (pAKT) and phospho-Y703 STAT3
(pSTAT3) were observed (Supplementary Figure 6). Although the
lack of detection of known factors of resistance in our in vitro and
in vivo analyses may be due to long-term treatments, we next
sought to analyze a different mechanism that could be common
to all models.
Given the transcriptomic changes observed across the in vivo
and in vitro models, the data were analyzed to identify alternative
regulators. A significant association (false discovery rate o5%)
was observed in the gene expression profiles from ortho-
xenograft samples and a target gene set of the ecotropic viral
integration site-1 (EVI1) proto-oncogene (Transfac V$EVI1_02;
Supplementary Figure 7). Similar associations for predicted EVI1
target sets were observed using data from the 4T1 tumors and
MCF7 cells (Supplementary Figure 7). Importantly, expression
analysis using TCGA data revealed positive correlations between
EVI1 and stem cell-like signatures (sMYC and from mammary
stem and progenitor cells),25 in addition to metastatic signatures,
Figure 3. Co-expression analysis and stem cell-like signatures. (a) TCGA network of significant co-expression levels (PCC P-values o0.05)
between TSC1 or TSC2 and signatures derived from stem cell-like cell studies (Supplementary Table 1). The nodes represent TSC1/2 and the
signatures, and the edges positive (red) or negative (green) correlations. Edge width is proportional to the corresponding PCC value.
(b) Clustering correlation of sESC, sMRS and sMYC. The ortho-xenografts are differentially clustered relative to the treatment, and a similar
trend is observed for 4T1 tumors. (c) The master regulators of the sMRS (that is, Core-9) are found to be relatively overexpressed upon mTOR
inhibition. (d) Significant overexpression of sESC, sMRS and sMYC in regrown ortho-xenografts after sirolimus treatment. The GSEA ESs and
the nominal P-values are shown. (e) Most of the regulators of sMRS are relatively overexpressed in everolimus-adapted HCC1937 cells.
(f) HMGA1, which is encoded in Core-9, is upregulated upon adaptation to mTOR inhibition, particularly in HCC1937 cells.
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including LMS-up,16 a signature from low-burden breast cancer
metastatic cells,10 and of breast cancer multipotency promoted by
oncogenic PI3KCA26,27 (Figure 4a). Moreover, a set of 79
commonly overexpressed genes (40.25 log2; Supplementary
Table 4) across the in vivo and in vitro models of mTOR inhibitor
resistance showed significant positive co-expression with EVI1
(Figure 4b). Of note, this set included LEF1, which regulates stem
cell maintenance in different contexts and is functionally
connected to SOXs.29 In addition, this set showed over-
representation of gene products involved in actin-cytoskeleton
remodeling (Supplementary Table 4).
EVI1 is essential for hematopoietic stem cell self-renewal30 and
its overexpression has been associated with worse recurrence-
free, overall and distant metastasis-free survival of ER-negative
breast cancer.31 In vitro depletion of EVI1 reduced the levels of
pS6, particularly in everolimus-adapted HCC1937 cells (60%
reduction, and MCF7 showed a reduction of 10% in any condition;
Figure 4c), whereas GFP-EVI1 overexpression conferred higher
cellular viability in response to everolimus (Figure 4d). Of note, the
levels of pS6 in the GFP-EVI1 overexpression assays were relatively
low (Figure 4d), which could be due to the lack of full adaptation
and/or the need for EVI1 co-factors.
To further validate the direct transcriptional role of EVI1,
chromatin immunoprecipitation (ChIP) assays of predicted tran-
scriptional targets were performed. This analysis revealed
increased (one-tailed P-valueso0.01) EVI1 binding at the follow-
ing loci with adaptation to everolimus in at least one cell model:
FSCN1 and SPARC (from the LMS-up); SCUBE3 and TCF4 (from V
$EVI1_02); and RHEB, RPS6KA1 and RAPTOR (from the mTOR
pathway) (Figure 4e). In addition, RAPTOR and RHEB were found to
be overexpressed as a function of everolimus adaptation in MCF7
and HCC1937 cells, respectively (Figure 4f; RAPTOR showed
transitory underexpression in HCC1937), and EVI1 depletion
reduced the expression of both proteins in the everolimus-
Figure 4. EVI1 couples stemness, metastatic potential and resistance to mTOR inhibition. (a) TCGA network of significant co-expression (PCC
P-values o0.05) between EVI1 and signatures derived from stem cell-like cells and/or metastatic settings (Supplementary Table 1).
(b) Distributions of PCCs between EVI1 and the commonly overexpressed 79 genes across the studied models or the complete microarray
gene list as background control. The P-value of the Mann–Whitney test for the comparison of the distributions is shown. (c) Reduced pS6
levels with EVI1 depletion in cell models. The quantification of pS6/S6 signal ratios is show at the bottom (relative to siControl). (d) Ectopic
overexpression of GFP-EVI1 in MCF7 (left panels) and HCC1937 (right panels) cells provides higher viability upon exposure to everolimus,
relative to GFP-only overexpression. Also shown are the western blot results for defined markers across the drug-exposed cell cultures. The
quantification of pS6/S6 signal ratios is show at the bottom (relative to TUBA per sample). (e) Increased EVI1 binding at predicted target
promoters/gene loci with adaptation to everolimus. The fold changes are relative to the immunoglobulin control and the promoter gene
targets are shown in the X axis. (f) Relative overexpression of RAPTOR and/or RHEB with adaptation to everolimus in MCF7 and HCC1937 cells.
The quantification is show at the bottom (relative to untreated and TUBA per sample). (g) Relative reduction of RAPTOR and RHEB expression
following EVI1 depletion, in particular in the everolimus-adapted setting.
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adapted settings (Figure 4g). However, the expression of FSCN1
was not significantly reduced with EVI1 depletion (Figure 4g) and,
in turn, EVI1 was found to be overexpressed with FSCN1 depletion
(Supplementary Figure 8). Therefore, these results may reflect the
initial response towards mTOR inhibition; in fact, a similar effect
was observed for RAPTOR and RHEB when EVI1 was depleted in
parental HCC1937 cells (Figure 4g, right panels).
EVI1 cooperates with SOX9
Based on the strong association between EVI1 and stem cell-like/
tumor initiation gene expression signatures, we searched for
potential EVI1-transcriptional target genes mediating such
functions. The V$EVI1_02 gene set and several other stem cell-
like cells and/or metastasis-associated gene signatures were
positively co-expressed with a key regulator of these functions,
SOX9 (Figure 5a).32,33 Subsequently, whole-genome EVI1 ChIP data
corroborated the positive correlation between EVI1 and SOX9
binding sites in HCC1937 cells (Supplementary Figure 9). Interest-
ingly, EVI1 ChIP data also showed a positive correlation with SLUG
targets34 in both cell models, and with SNAIL targets34 in HCC1937
(Supplementary Figure 9). Notably, MCF7 differentiation to a basal-
like phenotype requires SLUG activity.35
Expanding on the above results, sirolimus-treated ortho-
xenografts and everolimus-adapted cells showed increased
SOX9 expression compared with their corresponding controls
Figure 5. EVI1 cooperates with SOX9 and regulates its expression. (a) TCGA network of significant co-expression (PCC P-values o0.05)
between EVI1 or SOX9 and signatures derived from stem cell-like cells and/or metastatic settings (Supplementary Table 1). (b) Increased SOX9
expression in ortho-xenograft tumor fronts of mice treated with sirolimus; the results correspond to at least three ortho-xenografts of each
group. (c) Increased SOX9 and ALDH1 expression in everolimus-adapted cells. (d) Graph showing the results from the analysis of the complete
drug panel for the correlation between IC50 profiles and the expression of the V$EVI1_02 gene set; drugs are ranked according to PCC log
P-values. Negative and positive PCCs are indicated with different colors, and the mTOR inhibitors in the panel are denoted. (e) Left panel,
unsupervised clustering and correlation analysis of the difference in EVI1 ChIP results at the SOX9 locus between everolimus-adapted and
untreated cells. Right panels, results of ChIP assays targeting a predicted EVI1-binding site in the SOX9 promoter (Supplementary Table 5);
the input, control immunoglobulin immunoprecipitation (IP), and EVI1-IP results are shown. The control results for the binding site in FSCN1
are also shown. (f) Depletion of EVI1 leads to a reduction of SOX9 expression in three cell conditions (the results correspond to Figure 4c; the
ratios are relative to siControl and TUBA per sample). (g) Depletion of EVI1 leads to a reduction of colony-forming capacity. The results of
the one-tailed t-test are shown. (h) Depletion of Evi1 impairs the tumorigenic potential of 4T1 cells. The log-rank P-value is shown for the
comparison between the shControl and short hairpin RNA (shRNA)-EVI1 #1; note that transduction with shRNA-EVI1 #2 completely impaired
tumor formation so a P-value could not be computed (n.a.).
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(Figures 5b and c, respectively; the same antibody did not
recognize mouse Sox9). The expression of ALDH1—canonical
stem/progenitor marker in normal breast tissue and tumors, and
also associated with poor prognosis36—was also detected to be
increased with adaptation to everolimus in both MCF7 and
HCC1937 cells (Figure 5c). The higher expression at the tumor
invasive front is consistent with previous observations of invasive
leader cells showing positivity for basal/stem cell-like markers.10,37
In addition to the results from the models, the analysis of data
from hundreds of cell lines38 revealed significant positive
correlations between EVI1 and SOX9 expression, and with EVI1
locus copy number (PCCs 40.20, P-values o10− 4). Moreover, in
this data set, both EVI1 and SOX9 expression correlated positively
(that is, linked to resistance) with the half maximal inhibitory
concentration (IC50) of temsirolimus (PCCs = 0.22 and 0.24,
respectively, P-values o10− 4). In fact, a ranking-based analysis
using the V$EVI1_02 gene set as a surrogate of EVI1 activity
showed equivalent results, and the second and fourth most
correlated drugs, respectively, were BX-795 (inhibitor of PDK1
activity) and rapamycin (Figure 5d). To further assess these
findings, an ER-positive and HER2-positive breast cancer cell
model, BT-474, was exposed to 150 nM of everolimus for
approximately 100 days and subsequently profiled for gene
expression changes; the results showed significant associations
with EVI1 and SOX9 targets, and with the commonly over-
expressed genes detected across the above in vitro and in vivo
models (Supplementary Figure 10).
Further analysis of the predicted functional relationship
between EVI1 and SOX9 revealed a positive correlation in the
differential (between control and everolimus-adapted) binding of
EVI1 at the SOX9 locus (Figure 5e, left panel). Next, targeted ChIP
assays confirmed that EVI1 binds at the SOX9 locus in untreated
HCC1937 and both everolimus-adapted cell models (Figure 5e,
right panel). Thus, depletion of EVI1 reduced the expression of
SOX9 in three out of four conditions; however, it remains to be
determined which co-factor(s) may maintain SOX9 expression at
normal levels in everolimus-adapted HCC1939 cells (Figure 5f). In
parallel, depletion of EVI1/Evi1 reduced the colony-forming
capacity of both models of everolimus adaptation (Figure 5g)
and impaired in vivo tumorigenic potential of 4T1 cells (Figure 5h).
Collectively, ChIP, gene/protein expression analyses and in vivo
functional assays depict a link between EVI1 and SOX9 in the
regulation of stem cell-like and tumor initiation features.
In vivo evaluation of the EVI1, SOX9 and mTOR relationship
The functional cooperation between EVI1 and SOX9 was evaluated
in vivo using LM2 and 4T1 cells transduced with a short-hairpin
RNA scrambled control or directed against EVI1, and with or
without concomitant overexpression of Sox9 (mouse protein).
Thus, EVI1 depletion significantly reduced the capacity to colonize
the lungs, and concurrent Sox9 overexpression partially rescued
metastatic potential (Figures 6a and b). As shown in everolimus-
adapted cell lines, EVI1/Evi1 depletion caused a significant
decrease of both SOX9 and pS6 expression in the corresponding
metastasis (Supplementary Figure 11). Concurrent Sox9 over-
expression recovered pS6 signal in 4T1 but not in LM2 cells
(Supplementary Figure 11), which suggest differences in the
precise regulation of mTOR activity between the models.
In addition to EVI1, depletion of SOX9 in LM2 cells led to a
significant decrease in lung colonization capacity and, conversely,
Sox9 overexpression increased this capacity (Figure 6c and
Supplementary Figure 12). Depletion of Sox9 in 4T1 cells and
everolimus treatment of both cell models also reduced lung
colonization (Figures 6c and d). In addition, depletion of FSCN1 in
both models also led to a substantial impairment of lung
colonization (Figures 6e and f). Moreover, a greater effect was
observed when the animals were simultaneously treated with
everolimus (Figures 6e and f), which fully suppressed pS6 signal
(Supplementary Figure 11). Collectively, these results indicate that
transcriptional reprogramming mediated by EVI1-SOX9 is one of
the key factors in metastatic resistance to mTOR inhibition.
DISCUSSION
We provide evidence of the association between EVI1-SOX9
function, mTOR inhibition resistance and metastasis in breast
cancer. We also show that EVI1-SOX9-mediated transcriptional
reprogramming drives the molecular processes that support
breast cancer tumor initiation features and metastatic potential
in therapeutic resistance (Figure 7). These data are coherent and
expand on the concept that cancer stem cell-like cell populations
have high tumor-initiating capacity and are frequently the source
of therapy resistance and metastasis.39 Data from hundreds of cell
lines38 suggest that the proposed mechanism is relevant in
settings beyond breast cancer. Importantly, EVI1 maps in a
genomic region (including PI3KCA and SOX2) whose amplification
is an independent predictor of breast cancer recurrence.40 This
region is frequently found to be amplified in basal-like and BRCA1-
mutated breast cancer,21 as well as in non-small cell lung and
ovarian cancers.41 In addition, EVI1 amplification is independent of
PIK3CA mutations,41 which further reinforces the link with basal-
like breast cancer and is consistent with a role in resistance to
allosteric mTOR inhibition. It remains to be determined whether
EVI1 expression is upregulated through genomic amplification
and/or whether its function is enhanced by biochemical
modifications by casein kinase II42 and/or ERK signaling as seen
to be activated in our 4T1 assays.
Our preclinical findings and mechanistic model are consistent
with and expand on recent observations across different
neoplastic settings. EVI1 contributes to epithelial-to-mesen-
chymal transition (EMT) and invasion of acute myeloid
leukemia,43 and influences EMT in ovarian cancer cells,44 whereas
EMT mediates resistance to rapamycin.45 In the latter study, MCF7
cells transfected with constitute active SNAIL showed increased
ERK signaling and decreased sensitivity to rapamycin. Thus, our
study provides a mechanistic explanation for these observations.
In addition, it has recently been shown that SOX2 and SOX9
mediated the maintenance of latent metastatic stem cell-like
cells,46 and it was previously demonstrated that SLUG and SOX9
cooperatively determine mammary stem cell state,32 and that
SOX9 function links tumor initiation and invasion.33 Moreover, a
stem cell-like cancer phenotype that mediates breast cancer
metastasis is predicted to exhibit abnormal mTORC1 signaling10
and, in turn, mTORC1/2 inhibition promotes stem cell-like
properties and enhanced NOTCH1 activity in TN breast cancer cell
lines.12 Thus, enhanced mTOR signaling impairs cell differentiation
by potentiating NOTCH1 activity, and this signaling is found to be
increased in poorly differentiated breast tumors.14 Intriguingly,
NOTCH may also regulate SOX9 expression,47 which, in turn, is a
master regulator of stem and progenitor cells.48 In parallel,
allosteric mTOR inhibition increases the number of tumor-
initiating cells in a model of liver cancer15 and the metastatic
potential in a model of pancreatic neuroendocrine cancer.49 In this
scenario, our study proposes that EVI1 and SOX9 functionally
cooperate to sustain mTORC1 activity, EMT and metastatic
potential, thereby providing new insights into therapeutic
resistance.
Our findings—particularly those from MCF7 cell assays—may
have clinical implications for the established use of mTOR
inhibitors in endocrine-resistant ER-positive advanced metastatic
breast cancer,7 in which resistance to treatment is eventually
reported. Our results indicate that exposure to allosteric mTOR
inhibition selects a stem cell-like cancer cell population with
metastatic capacity, which may therefore promote disease
progression. Although in vivo assays may be warranted to further
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assess this observation, and while we cannot rule out that the
specific population may arise through the acquisition of new
mutations, it is noteworthy that the Breast Cancer Trials of Oral
Everolimus-2 (BOLERO-2) study for the efficacy of everolimus plus
exemestane in endocrine resistance showed similar benefits for
patients with or without visceral metastases.50 Nevertheless, full
and durable pathway inhibition—such as obtained that by the
next generation of targeted drugs51—may fully impair metastatic
resistance.
MATERIALS AND METHODS
Tissue microarray
The tissue microarray included 138 infiltrating ductal breast carcinoma
tumors collected at the Department of Pathology of the MD Anderson
Cancer Center, Madrid (Spain). The patients underwent surgery between
2003 and 2004, and all tumors were classified as grade 3. According to the
TNM system, 45 tumors belonged to stage I, 48 to stage II and 45 to stage
III-IV. The linked data included ER (n= 104), progesterone receptor (n=127)
and epidermal growth factor receptor 2 (HER2; n=125) status, and CK5
expression (n= 128), absence/presence of lymph node metastasis (n=124),
and absence/presence of distant metastasis (n= 127). The tissue microarray
contained duplicated cases and normal tissue, and the immunohisto-
chemical results were scored independently and blindly (to molecular and
clinical status). Selection of the highest value for a given case, blindly to its
status, solved discordant scores. The study was approved by the ethics
committee of the MD Anderson Cancer Center and written informed
consent was obtained from all patients.
Gene expression analyses
Pre-processed and normalized data of human breast cancer were taken
from the corresponding publication16 and from the TCGA repository
(http://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp).52 RNA samples were
extracted using TRIzol Reagent (Invitrogen, Karlsruhe, Germany) and
RNeasy Kit (Qiagen, Venlo, Netherlands), and quality was evaluated in an
Agilent Bioanalyzer (Foster City, CA, USA) 2100. The RNAs were amplified
using the Ribo-SPIA system (NuGEN Technologies Inc., San Carlos, CA, USA)
and subsequently hybridized on the Human Genome U219 microarray
platform (Affymetrix, Santa Clara, CA, USA; IRB Core Facility, Barcelona,
Spain). Gene expression data from the ortho-xenograft, and MCF7 and
HCC1937 cell lines have been deposited under the GEO reference
GSE39694. Gene expression data from the 4T1 tumors and BT-474 cells
have been deposited under the GEO references GSE50712 and GSE85801,
respectively. The GSEA and DAVID (for functional term analyses) tools were
used with standard parameters.53,54 The signature correlations were
computed by selecting genes with s.d. 41.0 and using the average Z-
score value per gene set. The quantification of NANOG, OCT4 and SOX2
gene expression was performed as previously described.55
Figure 6. In vivo assessment of the role of EVI1 and SOX9. (a, b) Depletion of EVI1/Evi11 expression (using two different short hairpin RNAs
(shRNAs)) in LM2 and 4T1 cells reduced lung colonization, and Sox9 overexpression partially recovered this potential, left panels. (a) Right
panels show representative images of lungs and their respective HE staining. (c) Depletion of SOX9 and overexpression of Sox9 reduced and
increased, respectively, lung colonization of LM2 cells. Treatment with everolimus of shControl LM2 cells also reduced lung colonization.
(d) Depletion of Sox9 or treatment with everolimus of 4T1 cells reduced lung colonization. (e, f) Depletion of FSCN1/Fscn1 expression in LM2
and 4T1 cells reduced lung colonization, and concurrent treatment with everolimus further impaired this potential.
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Antibodies
Anti-total and pAKT (#9272 and #9271, respectively, Cell Signaling
Technology, Danvers, MA, USA; #4060 for immunohistochemistry assays),
anti-ALDH1 (#611194, BD Biosciences, Oxford, UK), anti-4EBP1 (#9452, Cell
Signaling Technology), anti-p4EBP1 (#2855 and #9451, Cell Signaling
Technology), anti-ER (#IR151, Dako, Glostrup, Denmark), anti-total and
phospho-Thr202/Tyr204 ERK (#4695 and #4376, respectively, Cell Signaling
Technology), anti-EVI1 (#2265 and #2593, Cell Signaling Technology; and
#A301-691A, Bethyl Laboratories, Montgomery, TX, USA), anti-FSCN1
(#SC-56531, Santa Cruz Biotechnology, Dallas, TX, USA), anti-GFP ChIP
grade (#ab290, Abcam, Cambridge, UK), anti-GLUT1 (#652, Abcam), anti-
HER2 (#790-100, Ventana, Tucson, AZ, USA), anti-HMGA1 (#129153,
Abcam), anti-pIGF1R (#39398, Abcam), anti-IRS1 (#2382 and #9451, Cell
Signaling Technology), anti-KI67 (#IR626, Dako), anti-CK19 (#IR615, Dako),
anti-PR (#IR168, Dako), anti-RAPTOR (#SC-81537, Santa Cruz Biotechnology),
anti-RHEB (#SC-6341, Santa Cruz Biotechnology), anti-S6 (#SC-74459, Santa
Cruz Biotechnology), anti-pS6 (#4858, Cell Signaling Technology), anti-S6K
(#9202, Cell Signaling Technology), anti-pS6K (#9205, Cell Signaling
Technology), anti-SOX9 (#5535, Abcam), anti-total and pSTAT3 (#9132
and #9145, respectively, Cell Signaling Technology), anti-TUBA (#44928,
Abcam) and anti-VCL (V9131, Sigma-Aldrich, St Louis, MO, USA). The
antibodies used for fluorescence-activated cell sorting were anti-CD24-PE,
anti-CD44-APC, anti-CD49f-Alexa-647, and anti-EPCAM-FITC (#555428,
559942, 562473, and 347197, respectively; BD Biosciences).
Immunohistochemistry
The assays were performed on serial paraffin sections (3–4 μm thick) using
the EnVision (Dako) or Ultraview (Ventana) systems. Antigen retrieval was
performed using citrate- or EDTA-based buffers. Endogenous peroxidase
was blocked by pre-incubation in a solution of 3% H2O2 and blocking was
performed in 1X phosphate-buffered saline with 5% goat serum or 1%
bovine serum albumin and 0.1% Tween 20 (Sigma-Aldrich). In all
experiments, equivalent sections were processed without incubation with
the primary antibody, which did not reveal immunostaining in any case.
Sections were hematoxylin and eosin (HE)-counterstained and examined
with an Olympus BX51 (Tokyo, Japan) microscope. The immunohisto-
chemistry microscopic images were color deconvoluted and quantitated
using the regions of interest methodology in ImageJ (http://rsb.info.nih.
gov/ij). Quantification of tumor fronts was based on rectangular areas of
25 μM×50–300 μM. When quantifying the results from lung metastases, the
complete metastatic area was considered because the fronts were often
difficult to outline histologically.
Cell culture
The LM2 cell derivative is a lung metastatic sub-line originated from MDA-
MB-231 breast cancer cells from the laboratory of Professor Massagué.16
The 4T1 cells derived from a spontaneous BALB/c mouse breast cancer
tumor56 and were obtained from the ATCC (Rockville, MD, USA). The LM2
cells were cultured in Dulbecco's modified Eagle's medium (GIBCO,
Karlsruhe, Germany) supplemented with 10% fetal bovine serum (GIBCO),
1x L-glutamine (Biowest, Nuaillé, France) and 1% penicillin/streptomycin
(Biowest). The 4T1 cells were cultured in Roswell Park Memorial Institute
(RPMI)-1640 medium (Sigma-Aldrich) supplemented with 10% fetal bovine
serum, 1x L-glutamine and 1% penicillin/streptomycin. All MDA-MB-231
cells/sub-lines were stably transfected with a thymidine kinase and GFP
luciferase construct and sorted for GFP expression. The MCF7 and
HCC1937 cell lines were obtained from ATCC and cultured in supplemen-
ted Dulbecco's modified Eagle's medium and RPMI-1640 medium,
respectively. The Matrigel (BD Biosciences) colony formation assays were
performed using standard protocols with 5% fetal bovine serum.
Everolimus was purchased from Selleck Chemicals (Houston, TX, USA)
and LC Laboratories (Woburn, MA, USA). Fluorescence-activated cell
sorting was performed using FACS Canto (Becton Dickinson, Franklin
Lakes, NJ, USA) and Diva software (Becton Dickinson) package, and
antibody-based cell labeling was performed as previously described.55
Western blotting
To analyze extracts, cells were lysed in standard 150 mM NaCl buffer
supplemented with protease inhibitor cocktail (Roche Molecular Biochem-
icals, Mannheim, Germany) and, in some instances, a phosphatase inhibitor
was added (1 mM NaF, Sigma-Aldrich). Lysates were clarified twice by
centrifugation at 13 000× g and protein concentration was measured
using the Bradford method (Bio-Rad, Solna, Sweden). Lysates were
resolved in sodium dodecyl sulfate–polyacrylamide gel electrophoresis
gels and transferred to Immobilon-P (Merck Millipore, Billerica, MA, USA) or
PVDF membranes (Roche Molecular Biochemicals). Target proteins were
identified by detection of horseradish peroxidase-labeled antibody
complexes with chemiluminescence using the ECL Western Blotting
Detection Kit (GE Healthcare, Amersham, UK).
Lung colonization assays
The Animal Care and Use Committee of IRB Barcelona approved the
following animal studies. Female BALB/c nude (MDA-MB- 231 cells) or
BALB/c wild-type mice (4T1 cells) were used. For tail vein injections, cells
were suspended in 1x phosphate-buffered saline (GIBCO; 200 μl per
mouse) and injected into the lateral tail vein of mice using a 26G needle, as
previously described.57 Before the injection of cells, mice were anesthe-
tized with ketamine (100 mg/kg body weight) and xylazine (10 mg/kg
body weight), and immediately after injection they were imaged for
luciferase activity by injecting 50 μl of beetle luciferin potassium salt
(Promega, Madison, WI, USA) at 15 mg/ml. To induce the expression of
short hairpin RNA in vivo, doxycycline (1 mg/ml, Sigma-Aldrich) was
administered ad libitum in drinking water containing 25 mg/ml sucrose
(Sigma-Aldrich). When indicated, DMSO solution (at the same concentra-
tion as for the compound test, 5%) or everolimus (5 mg/kg; SC-218452,
Santa Cruz Biotechnology) was administered daily by intraperitoneal
injection. Mice were monitored weekly using IVIS imaging, unless
otherwise indicated. Lung tumor development was followed up once a
week by bioluminescence imaging of the upper dorsal region that
corresponds to lung position. Bioluminescent images were quantified with
Living Image 2.60.1 software (Perkin-Elmer, Waltham, MA, USA). All values
were normalized to those obtained at day 0. The HE staining of lung
sections scored the lung colonization capacity of 4T1 cells 3 weeks post-
inoculation. Five sections, separated by 50 μm, per mouse lung were
counted. The average of the total metastatic area normalized to total lung
area was measured. The average total lung metastasis area for all mice was
then plotted. The tissue was dissected, fixed in 10% buffered formalin
(Sigma-Aldrich), and embedded in paraffin. Sections (3 μm thick) were
stained with HE. To analyze the metastatic area, images were taken with a
scanner, and the area of each metastatic lesion was quantified with the
ImageJ software. Five images per section/animal were evaluated, and the
average area was plotted. The Fiji Trainable Weka segmentation, an ImageJ
plugin based on the Weka58 Java machine learning library, was used to
classify images on the basis of local colorimetric, textural and structural
features in the neighborhood of each pixel. Images were processed with a
custom macro created at the Microscopy Core Facility of IRB Barcelona.
Figure 7. Proposed mechanistic model. In untreated cancer, low
TSC1/2 expression is associated with enhanced mTORC1 activity and,
therefore, with a primary metastatic and stemness phenotype. In
cancer treated for mTOR inhibition, EVI1-SOX9 become activated (in
part by overexpression) and positively sustain the following
features: mTOR signaling (through upregulation of RHEB and
RAPTOR), metastatic potential (through LMS-up and other signa-
tures) and stemness (through at least SOX9).
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The two-tailed non-parametric Mann–Whitney test was used to assess
significance of the immunohistochemical staining results.
Ortho-xenograft
The patient was a 33-year-old woman with a pathological germline BRCA1
mutation and diagnosed with breast cancer shortly after pregnancy. At
diagnosis she presented a locally advanced TN ductal infiltrating
carcinoma of the breast (T4) with involvement of ipsilateral nodes (N2)
and lung metastasis. Primary systemic chemotherapy was initiated with
TAC regimen for four cycles, followed by mastectomy to prevent local
complications because of extensive breast involvement. Following surgery,
the patient received further chemotherapy with the same regimen. The
patient was diagnosed with brain metastases shortly after and died
8 months post-diagnosis as a result of disease progression. Mutational
analysis of BRCA1 was carried out by the Molecular Diagnostics Unit
(Catalan Institute of Oncology, Barcelona, Spain) following standards for
genetic testing and pathological determination. The patient provided
written informed consent, and the study was approved by the IDIBELL
Ethics Committee. Female athymic (nu/nu) mice (Harlan, Harlan Labora-
tories, Barcelona, Spain) between 4 and 6 weeks of age were used for
engraftment. The orthotopic model developed histologically detectable
lung metastases in a period of approximately 50 days after engraftment.
The protocol was reviewed and approved by the IDIBELL Animal Care and
Use Committee. A daily oral treatment with sirolimus (Rapamune) or
control solution (DMSO, Sigma-Aldrich) was applied.
Exome analysis
The National Centre for Genomic Analysis (CNAG) carried out exome
sequencing. Sequence capture and amplification was performed using
Agilent (Agilent Technologies, Palo Alto, CA, USA) SureSelect Human All
Exon kit (Agilent) according to the manufacturer’s instructions. Paired-end
sequencing was performed on a HiSeq2000 instrument (Illumina, San
Diego, CA, USA) using 76-base reads. Reads were aligned to the reference
genome (GRCh37) and BAM files were generated using SAMtools.
Duplicates were removed using SAMtools and custom scripts, and
single-nucleotide variant calling was performed using a combination of
SAMtools and Sidrón algorithms as described previously.59 The reads were
first aligned to mouse genome (mm9), and those read-pairs that did not
align to mouse were then aligned to the human genome following the
same pipeline as above. Only mismatch variants were taken into account
and small insertions and deletions were not counted. Common variants,
defined as those present in dbSNP135 with a minor allele frequency4 1%,
were filtered out.
4T1 tumors
The animal studies were conducted using protocols that had undergone
appropriate review and approval at the New York University School of
Medicine. Balb/C mice were injected subcutaneously with 5 × 104 4T1 cells,
measured for tumor size at day 10, and randomly organized in two
equivalent groups that were treated with DMSO solution (the same
concentration as for the compound test) or everolimus (5 mg/kg;
SC-218452, Santa Cruz Biotechnology) daily by intraperitoneal injection.
Tumors were excised at day 23 and processed. Half of each tissue sample
was used for immunohistochemistry and half for gene expression
microarray analysis. For the tumorigenicity assays, 250 000 4T1 cells were
injected at the orthotopic site, mixed with growth factor-reduced Matrigel
(BD Biosciences) before inoculation (1:1). Once palpable, tumors were
measured with a digital caliper, and the tumor volume was calculated. The
ethics committee of the CIC bioGUNE approved these assays.
ChIP assays
Assays were prepared using 107 cells of each cell line per condition.
Chromatin was fragmented by sonication (Bioruptor, Diagenode, Denville,
NJ, USA) for 30 min (30-s pulses, 30-s pauses) and assays were carried out
following the manufacturer’s protocol (kch-mahigh-A16, HighCell# ChIP Kit,
Diagenode), using anti-EVI1 (#2593, Cell Signaling Technology) or an equal
amount of IgG isotype as negative control (#2729, Cell Signaling
Technology). The amount of DNA was analyzed by real-time polymerase
chain reactions using SYBR Green-based assays (Applied Biosystems, Life
Technologies, Foster City, CA, USA). The results were calculated using the
ΔCt method. A genomic region of the GAPDH gene was used as negative
control (Diagenode). The corresponding human genome coordinates,
EVI1-binding sites and primers designed for the assays are detailed in
Supplementary Table 5. Whole-genome ChIP data were obtained by
hybridization to SurePrint G3 Human Promoter 1x1M microarrays
(IRB Core Facility) and analyzed by MACS (version 2.0.9).60 The data
have been deposited under the GEO reference GSE50905. The complete
ranking of differential EVI1 binding between adapted and sensitive
MCF7 or HCC1937 cells was used as input for the GSEA of transcription
factor targets.
Gene expression alterations
Stable LM2 and 4T1 cell lines expressing short hairpin RNAs were
generated as described previously.57 The shFSCN1/Fscn1 (that is, targeting
both human and mouse gene expression) #1 and shEVI1/Evi1 #2 were
encoded in lentiviral vectors (inducible pTRIPZ lentiviral short hairpin RNAs,
GE Dharmacon, Lafayette, CO, USA). The short hairpins were induced by
1 μg/ml doxycycline for 72 h. The shControl and shEVI1/Evi1 #1 were
encoded in a retrovirus pGFP-V-RS (OriGene, Rockville, MD, USA). The
shFSCN1/Fscn1 #1 was encoded in a pSUPER (Addgene, Cambridge, MA,
USA) vector. The shSox9 (against mouse gene sequence) and shSOX9
(human) were obtained from the MISSION library (SHCLND-NM_011448
and SHCLND-NM_000346, respectively; Sigma-Aldrich). An additional
shSOX9 was obtained from Addgene, catalog #40644. For Sox9 over-
expression, the corresponding coding sequence was cloned into a
lentiviral pWXL vector. Stable cell lines expressing the various constructs
described above were generated under puromycin selection for 48 h. The
siRNA against EVI1 expression was an ON-TARGETplus SMARTpool
(L-006530-02-0010, Dharmacon). The following primer sequences were
used to assess gene expression changes in real-time (using SYBR Green,
Applied Biosystems) polymerase chain reaction assays: EVI1, 5′-CATT
GGGAACAGCAACCAT-3′ and 5′-GGTCACCAAAGCCTTTTCAT-3′; Evi1, 5′-CAC
AGAAAGTCCAAATCACAGG-3′ and 5′-GCCACACGTTGGAGGAAC-3′; Sox9,
5′-GTACCCGCATCTGCACAAC-3′ and 5′-CTCCTCCACGAAGGGTCTCT-3′; ACTB,
5′-GGAGTGGGTGGAGGCAG-3′ and 5′-AACTAAGGTGTGCACTTTTGTTC-3′; and
mL32, 5′-GAAACTGGCGGAAACCCA-3′ and 5′-GGATCTGGCCCTTGAACCTT-3′.
Genomics of drug sensitivity data analyses
For the correlation analysis between the basal expression of EVI1, its
predicted target genes and the drug responses across cancer cell lines,
data were downloaded from the GDS project (web-release April 2012).38
This data set included IC50 values for 131 drugs that were assessed in a
panel of 638 human cancer cell lines. The basal gene expression data were
downloaded from ArrayExpress reference E-MTAB-783. Non-annotated
probes were removed and expression values were averaged when multiple
probes mapped to the same gene. Correlation scores and P-values were
computed using the PCC. The EVI1 target set included 20 genes that were
represented by at least one microarray probe (Supplementary Table 6). The
extent of the basal expression of the EVI1 targets was quantified using an
enrichment score (ES) computed with a Matlab implementation of the
GSEA algorithm. To estimate ES significance, a null model was created by
generating 10 000 random gene sets (of the same size as the EVI1 target
set) and used to query the data set through GSEA. Next, two inverse
Gaussian distributions (for positive and negative ES values) were fitted on
the resulting empirical distribution and used to compute P-values. The
correlations between IC50 profiles and ESs were computed by considering
only cell lines whose basal expression profile yielded a significant ES
(Po0.05), according to the null model. The enrichment P-values of mTOR
inhibitors among drugs whose IC50 profile was anti-correlated with the
EVI1 target ES were computed using Fisher’s exact test and considering the
total set of 131 drugs.
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